T
Torben Plesner
Researcher at University of Southern Denmark
Publications - 205
Citations - 11134
Torben Plesner is an academic researcher from University of Southern Denmark. The author has contributed to research in topics: Daratumumab & Multiple myeloma. The author has an hindex of 45, co-authored 186 publications receiving 9295 citations. Previous affiliations of Torben Plesner include University of Copenhagen & Finsen Laboratory.
Papers
More filters
Journal ArticleDOI
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia
Henrik Birgens,Henrik Frederiksen,Hans Carl Hasselbalch,Inge Helleberg Rasmussen,Ove Juul Nielsen,Lars Kjeldsen,Herdis Larsen,Torben Mourits-Andersen,Torben Plesner,Dorthe Rønnov-Jessen,Hanne Vestergaard,Tobias Wirenfeldt Klausen,Claudia Schöllkopf +12 more
TL;DR: The data show that using rituximab and prednisolone combined rather than predisonsolone alone as first‐line treatment in WAIHA increases both the rate and the duration of the response.
Journal ArticleDOI
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network
Niels W.C.J. van de Donk,Antonio Palumbo,Hans Erik Johnsen,Monika Engelhardt,Henrik Gregersen,Roman Hájek,Martina Kleber,Heinz Ludwig,Gareth J. Morgan,Pellegrino Musto,Torben Plesner,O. Sezer,Evangelos Terpos,Anders Waage,Sonja Zweegman,Hermann Einsele,Pieter Sonneveld,Henk M. Lokhorst +17 more
TL;DR: Clonal burden, as determined by bone marrow plasma cell percentage or M-protein level, as well as biological characteristics, including heavy chain isotype and light chain production, are helpful in predicting risk of progression of monoclonal gammopathy of undetermined significance to symptomatic disease.
Journal ArticleDOI
Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group
Jens Hillengass,Lia A. Moulopoulos,Stefan Delorme,Vassilis Koutoulidis,Jennifer Mosebach,Thomas Hielscher,Matthew T. Drake,S V Rajkumar,B Oestergaard,Niels Abildgaard,Maja Hinge,Torben Plesner,Yasuhito Suehara,Kosei Matsue,Nadia Withofs,Jo Caers,Anders Waage,H. Goldschmidt,Meletios A. Dimopoulos,Suzanne Lentzsch,Brian G.M. Durie,E. Terpos +21 more
TL;DR: WBCT (either computed tomography (CT) alone or as part of a positron emission tomography-CT protocol) should be considered the current standard for the detection of osteolytic lesions in MM.
Journal ArticleDOI
In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: A cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients
Carsten Geisler,Preben Philip,B. Egelund Christensen,Klaus Hou-Jensen,N. Tinggaard Pedersen,O. Myhre Jensen,K. Thorling,Erik Andersen,Henrik Birgens,Aage Drivsholm,Jørgen Ellegaard,Jørgen K. Larsen,Torben Plesner,Peter de Nully Brown,P. Kragh Andersen,M. M. Hansen +15 more
TL;DR: In patients with typical CLL immunophenotype, chromosome abnormalities are somewhat less frequent at the time of diagnosis than hitherto believed, but chromosome 17 abnormalities suggest a poor prognosis.
Journal ArticleDOI
Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue.
Torben Plesner,Elisabeth Ralfkiaer,Minna Wittrup,Hans Erik Johnsen,Charles Pyke,Trine L. Pedersen,Niels Ebbe Hansen,Keld Danø +7 more
TL;DR: UPAR is a differentiation marker for myeloid and monocytic cells, and may act to facilitate migration of these cells in normal and pathologic conditions by cell-associated plasminogen activation.